Core Viewpoint - French luxury group Kering is acquiring family-owned jewelry producer Raselli Franco Group with an initial investment of 115 million euros ($134.76 million) [1] Company Summary - Kering is expanding its portfolio in the luxury sector by purchasing Raselli Franco Group, a family-owned jewelry producer [1] - The acquisition reflects Kering's strategy to enhance its presence in the jewelry market, which is a growing segment within the luxury industry [1] Financial Summary - The initial investment for the acquisition is set at 115 million euros, equivalent to approximately 134.76 million dollars [1]

New IPOs - The largest biotech IPO in Hong Kong for 2025 is initiated by Insilico Medicine (03696), which boasts the fastest global progress in AI drug development [1] - Lin Qingxuan (02657) will conduct its IPO from December 18 to December 23, attracting cornerstone investors like Fidelity [1] - Woan Robotics (06600) is set to launch its IPO during the same period, with an expected listing date of December 30 [1] - Meilian Holdings (02671) and Wuyi Vision (06651) will also hold their IPOs from December 18 to December 23, both expected to list on December 30 [1] - Xun Ce (03317) will follow the same IPO schedule, with a listing anticipated on December 30 [1] - Zhihui Mining (02546) achieved a remarkable 5248.15 times subscription in its public offering, with a listing date of December 19 [1] - China National Airlines (00753) plans to invest in Shenzhen Airlines' equity financing, with Kunhang Investment, a state-owned entity, being shortlisted [1] - Sensetime-W (00020) intends to place 1.75 billion new Class B shares, aiming to raise approximately HKD 3.146 billion [1] - Fosun Pharma (02196) is enhancing its overseas innovative drug strategy by signing a cooperation and option agreement with Clavis Bio [1] - WuXi AppTec (02359) invested around EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [1] - Minhua Holdings (01999) plans to acquire 100% equity in the American soft furniture company Gainline Recline Intermediate Corp [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.055 million shares for HKD 636 million on December 18 [2] - Xiaomi Group-W (01810) spent HKD 151 million to buy back 3.75 million shares on the same day [2] - COSCO Shipping Holdings (01919) repurchased 5.9 million shares for HKD 80.557 million [2] - Country Garden Services (06098) bought back 2.7 million shares for HKD 17.136 million [2] - Jiangsu Ninghu Expressway (00177) saw an increase of 52.862 million shares by Yunsong Capital [2]

Group 1 - The company announced that its indirect wholly-owned subsidiary, Minhua American Manufacturing, has entered into a purchase agreement to acquire 100% of the issued share capital of Gainline Recline Intermediate Corp for $32 million [1] - At the time of closing, the seller provided a repayment letter indicating that the total amount required to settle all outstanding obligations under the bank financing obtained by the target group is $27,993,885.51 [1] - The company will provide an interest-free loan of $26,670,335.51 to the target group to fully repay the aforementioned bank financing obligations, with the remaining balance of $1,323,550 to be settled by the target group using available bank cash at closing [1] Group 2 - The target group primarily engages in the manufacturing and sale of soft furniture in the United States, operating eight production facilities in northern Mississippi with a total area exceeding 2 million square feet [2] - The board anticipates that the acquisition will create synergies between the company and the target group, and it will expand the company's production layout in the U.S. to address opportunities and challenges arising from changes in the international trade environment [2] - The board believes that the terms of the purchase agreement are normal commercial terms, fair, reasonable, and in the overall interest of the company's shareholders [2]

Acquisition Overview - Stockwik Förvaltning AB has entered into an agreement to acquire all shares in Labino Aktiebolag, a leading Swedish manufacturer of UV-A lights for industrial use, particularly in non-destructive testing in the aviation industry [1] - The acquisition is subject to clearance under the Swedish Screening of Foreign Direct Investments Act and is expected to be completed in February 2026 [1] Company Performance - Labino generates revenue of approximately SEK 35 million and has demonstrated good profitability [2] - The company serves a global customer base, including airplane manufacturers, airlines, oil and gas companies, and automotive companies, and its products are also utilized in cleanrooms and forensic investigations [2] Strategic Intent - Stockwik's President and CEO, Urban Lindskog, expressed enthusiasm about welcoming Labino into the Stockwik family and emphasized the importance of supporting Labino's long-term development [3] - The acquisition marks Stockwik's first company acquisition in three years, complementing its organic growth strategy following refinancing and a capital injection [3] Future Projections - The acquisition is anticipated to contribute SEK 0.32 in earnings per share after a directed share issue completed in November 2025 [4] - Labino's CEO, Lisel Athanasiadis, highlighted that the company is experiencing its best year ever and is optimistic about future growth under Stockwik's ownership [4]

Group 1 - The company Dongwei Semiconductor (688261.SH) announced plans to acquire 117,300 shares of Suzhou Denglin Technology Co., Ltd. at a price of 85.2378 yuan per share, totaling an investment of 10 million yuan [1] - The actual controller, Mr. Gong Yi, and a major shareholder, China-Suzhou Industrial Park Venture Capital Co., Ltd., will also acquire shares from the same seller, with respective investments of 3.52 million yuan and 50 million yuan [1] - Upon completion of the transactions, the company will hold 0.2175% of Suzhou Denglin, while Mr. Gong Yi and China-Suzhou Venture Capital will hold 0.0652% and 4.3998% respectively [1]

南财智讯12月18日电，白云山（00874.HK）发布须予披露交易公告，于2025年12月17日，公司子公司 广州医药股份有限公司与浙江海正药业股份有限公司订立《股权交易合同》，拟通过公开挂牌方式收购 浙江省医药工业有限公司100%股权，交易对价为人民币5.005亿元。其中8600万元已作为竞买保证金支 付并转为部分对价，剩余4.145亿元将在合同生效后五个工作日内一次性支付至台州市产权交易所有限 公司指定账户。本次交易构成白云山的须予披露交易，但未达到股东批准标准。目标公司为浙江省排名 前六的优质医药流通企业，最近一年销售收入超40亿元，收购有助于广州医药完善华东区域布局，提升 终端市场覆盖能力。本次收购资金来源于广州医药自有资金，董事会认为交易条款公平合理，不会对公 司财务及经营状况产生不利影响，符合公司及股东整体利益。 ...

据摩洛哥360网站12月15日报道，Marsa Maroc与西班牙Boluda集团宣布达 成战略协议，Marsa Maroc旗下全资国际物流公司（MMIL）将以8000万欧元收 购Boluda码头公司45%的股权。此次收购旨在加强摩洛哥-西班牙海运走廊这一 关键通道，并利用双方在码头管理与综合物流上的专长，为开拓国际（尤其是 非洲）市场创造机遇。 （原标题：Marsa Maroc收购西班牙Boluda码头公司45%股权） Boluda码头公司在伊比利亚半岛至加那利群岛之间运营着九个码头，分别 位于拉斯帕尔马斯、特内里费、加的斯、桑坦德和塞维利亚等地，2024年集装 箱吞吐量超100万标准箱。其背后的Boluda航运公司旗下拥有连接欧洲、非洲 岛屿及西非沿岸的11条航线网络。通过此次收购，Marsa Maroc的全球业务网 络扩增至20个港口、35个码头。 ...

白云山（600332）(00874)公布，于2025年12月17日，买方(广州医药，公司子公司)与卖方(海正药业 （600267），公司独立第三方)订立了股权交易合同及补充协议。根据股权交易合同及补充协议，买方 拟收购浙江省医药工业有限公司100%股权，收购对价为约人民币5.005亿元。于收购事项完成后，买方 将持有目标公司100%股权。 公告称，目标公司位于长三角地区，医药市场发达，是浙江省排名前六的优质医药流通企业。目标公司 长期深耕浙江省市场，积累了丰富的客户资源，最近一年年销售收入规模超过人民币40亿元，具有良好 发展前景;收购事项有利于广州医药获取浙江省及周边地区成熟的客户网络，进一步优化在华东区域的 产业佈布局，提升对国内终端市场的覆盖广度和深度。 ...

Core Viewpoint - The acquisition of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd. by Guangzhou Pharmaceutical is a strategic move to enhance market presence in the East China region, with a transaction value of RMB 500 million [1] Group 1: Acquisition Details - Guangzhou Pharmaceutical, a subsidiary of the company, has entered into a share purchase agreement to acquire 100% equity of Zhejiang Pharmaceutical from Haizheng Pharmaceutical for RMB 500 million [1] - The acquisition is set to be completed by December 17, 2025, after which Guangzhou Pharmaceutical will hold full ownership of the target company [1] Group 2: Target Company Overview - Zhejiang Pharmaceutical is a leading pharmaceutical distribution enterprise in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products [1] - The company reported annual sales revenue exceeding RMB 4 billion in the past year, indicating a strong growth potential [1] Group 3: Strategic Rationale - The acquisition price reflects a premium over the assessed value, which the company considers reasonable based on several factors [1] - The target company is ranked among the top six pharmaceutical distribution enterprises in Zhejiang, providing a well-established customer network and market presence [1] - This acquisition will enable Guangzhou Pharmaceutical to optimize its industrial layout in East China and enhance coverage in the domestic terminal market [1]

Group 1 - Warner Bros. Discovery (WBD) shares fell by 0.8% on Wednesday morning [1][2] - The WBD board urged shareholders to reject the hostile takeover bid from Paramount Sky Dance (PSKY) at $30 per share, valuing the equity at approximately $108.4 billion, citing financing risks [1][2] - The WBD board reaffirmed its support for the cash and stock deal with Netflix (NFLX) regarding WBD's streaming and film production assets, with an equity value of about $72 billion and an enterprise value of approximately $83 billion [1][2]